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To understand the real impact of COVID-19 on cancer patients, an entirely new data collection effort was initi-
ated within the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT). TERAVOLT reported
high mortality related to COVID-19 infection in thoracic cancer patients and identified several negative prog-
nostic factors. In this commentary, we discuss the importance and limits of patient registries to support de-
cision-making in thoracic cancer during the SARS-CoV-2 pandemic.In the midst of the severe acute respira-
tory syndrome coronavirus 2 (SARS-
CoV-2) pandemic, oncologists have had
to rapidly restructure their work to opti-
mize safe delivery of care for their cancer
patients, weighing the risks of morbidity
from coronavirus disease 2019 (COVID-
19) against the benefit of intended cancer
therapies. From the onset of the
pandemic, patients with cancers ap-
peared to be at increased risk for more
serious illness with COVID-19 (Kuderer
et al., 2020; Tian et al., 2020; Luo et al.,
2020; Wang et al., 2020; Sica et al.,
2020; Mehta et al., 2020). In such a
chaotic time, with insufficient quality
data available and limited knowledge of
the SARS-CoV-2 infection, understanding602 Cancer Cell 38, November 9, 2020 ª 202the real impact of COVID-19 on cancer
patients had quickly become a challenge
for the thoracic cancer community. To
support decision-making, an entirely
new data collection effort was initiated
within the Thoracic Cancers International
COVID-19 Collaboration (TERAVOLT)
(Whisenant et al., 2020; Garassino
et al., 2020).
Two months after conception, the
TERAVOLT group had enrolled 200 pa-
tients from 42 institutions across eight
countries (Italy, Spain, France,
Switzerland, the Netherlands, USA, UK,
and China). Garassino et al. (2020) re-
ported a 33%mortality rate and a low pro-
portion of thoracic cancer patients
receiving intensive care or mechanical0 Elsevier Inc.ventilation. Only smoking seemed to
significantly correlate with higher death
rates (Garassino et al., 2020). Results
from 1,000 patients were presented at
the European Society of Medical
Oncology (ESMO2020) virtual congress
and confirmed the significantly high mor-
tality related to COVID-19 among the
thoracic cancer patients included in the
registry, evaluated at 32% (N = 326;
note that a large proportion of patients
were diagnosed early in the pandemic in
the first wave in Europe and North Amer-
ica). The results of the multivariate anal-
ysis (Table 1) suggested that Eastern
Cooperative Oncology Group (ECOG)
performance status R2 (OR 3.6: 95% CI
2.7–5), smoking history (OR 1.8: 95% CI
Table 1. Multivariable Model of Factors Associated with Death
Clinical and Demographic
Characteristics Reference Levels Odds 95% CI p
ECOG at COVID-19
diagnosis
R2 versus <2 3.6 2.7–5.0 <0.001
Stage at COVID-19
diagnosis
IV versus %III 1.9 1.4–2.7 <0.001
Smoker Former or current
versus never
1.8 1.2–2.7 <0.01
Prior steroids Yes versus no 1.7 1.1–2.0 <0.01
Age >65 versus %65 1.5 1.1–2.0 0.01
Oncological treatment None or chemotherapy
versus immunotherapy,
chemo + immuno, or target
1.4 1.02–2.0 0.03
Commentary
ll1.2–2.7), stage IV (OR 1.9: 95% CI 1.4–
2.7), age >65 (OR 1.5: 95% CI 1.1–2.0),
steroids >10 mg (OR 1.7: 95% CI 1.1–
2.0), and chemotherapy or no treatment
were significantly associated with nega-
tive outcomes. The role of anticoagulants
and steroids at COVID-19 diagnosis is still
under debate.
As of September 2020, despite differ-
ences in healthcare delivery and improve-
ment in our understanding of how to
manage patients infected with SARS-
CoV-2, and timing of data collection
during this lasting pandemic, mortality un-
fortunately remains high, and factors
influencing mortality remain consistent.
The registry was important for address-
ing oncologists’ questions about the
impact of COVID-19 on the outcomes of
patients with thoracic malignancies.
Based on the preliminary results, we are
now more confident in delivering tyrosine
kinase inhibitors and immunotherapy and
more careful in administering chemo-
therapy to patients with ECOG PS2. We
are now aware that mortality is high, that
we must stress self-isolation and other
strategies to avoid infection, and that we
must spend the necessary time to
educate patients and families.
The international nature of this registry
(as of September 11, 2020, 211 centers
across 20 countries and six continents),
with the engagement of academic and
community oncological centers as well
as the endorsement of key medical soci-
eties such as International Association
for the Study of Lung Cancer (IASLC), Eu-
ropean Society for Medical Oncology
(ESMO), European Thoracic Oncology
Platform (ETOP), and European Respira-
tory society (ERS), was vital to the rapid
enrollment of cases. However, globalengagement required the collection of
manageable and comparable data. The
information recorded is based on an
extensive literature review and reflects
daily clinical practice at different cancer
centers worldwide. The data collection
focused on thoracic malignancies, mainly
lung cancers, in order to guarantee the
uniformity of the study population.
Furthermore, to ensure the quality of the
registry, TERAVOLT has established a
data management system, including
database managers, statisticians, and
epidemiologists, to cover such aspects
as data collection, data quality controls,
error correction, data analyses, and re-
porting. A scientific steering committee
has been established to ensure the timely
dissemination of results and the effective,
appropriate, and transparent use of data
collected. Furthermore, the availability of
similar or common clinical practice guide-
lines, the existence of standard protocols
of care for thoracic malignancies acces-
sible worldwide, and the involvement of
academic cancer centers in Western
countries have helped minimize possible
information bias related to the treatment
of the enrolled patients. Comprehensive
knowledge of the predictive and prog-
nostic factors for lung cancer ensured
adjustment for known confounding fac-
tors at the time of analyses.
After over 6 months of a global
pandemic, it seems clear that patient reg-
istries, such as TERAVOLT, by observing
real-world clinical practice, may collect
the information necessary to evaluate pa-
tient outcomes in a generalizable manner.
To correctly interpret this information,
however, the potential sources of bias
(selection and information) that challenge
observational studies need to be ad-dressed. In this regard, TERAVOLT regis-
try also has some limitations. It includes
patients from countries with different so-
cioeconomic levels and data from both
academic and community hospitals;
thus, it is not immune to generalizability is-
sues. The first 200 TERAVOLT patients
weremostly fromEurope andweremostly
registered from Italy, France, and Spain
during the initial wave of the pandemic,
which nearly overwhelmed the health
care systems at that time. Thus, the
geographical locations included in the
initial cohort could partially explain the
low number of intensive care unit admis-
sions observed (Garassino et al., 2020).
Since the first publication, the countries
contributing to TERAVOLT have
increased significantly, including 20 coun-
tries across Europe and North and South
America and a limited number from Asia
and the rest of the world. As the pandemic
continues to evolve, patient enrollment
has been and will continue to be clearly
determined by the geographical spread
of SARS-CoV-2.
As of September 2020, the majority of
patients enrolled in TERAVOLT had stage
IV non-small cell lung cancer and were on
systemic treatment. Thus, these patients
are not representative of the entire popu-
lation of lung cancer patients. TERAVOLT
is largely organized by medical oncolo-
gists, and therefore the patient population
naturally tends to be characterized more
by patients with advanced stage lung
cancer. Furthermore, the initial limited
and subsequently growing knowledge
about the pathology and natural history
of SARS-CoV-2, together with increasing
experience in treatment of the infection
and evolution of surveillance criteria,
may have influenced the collection of
data regarding SARS-CoV-2 infection.
To improve its generalizability, TERA-
VOLT is strengthening the collaboration
between oncologists and other health
care providers such as pulmonologists,
surgeons, and radiation oncologists and
is considering expanding the partnership
with external data sources to validate
key assumptions (e.g., the Observational
Health Data Sciences and Informatics
[OHDSI], https://ohdsi.org/who-we-are/;
openSAFELY, https://opensafely.org/;
the Cancer Consortium [CCC-19], etc.).
In addition, TERAVOLT is envisioning
long-term data collection to adequately
contextualize the results of the registryCancer Cell 38, November 9, 2020 603
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llin pandemic waves and to adapt
data collection over time to capture
additional information. TERAVOLT inves-
tigators have also launched an interna-
tional patient questionnaire to determine
perceived impact of the pandemic on their
cancer care. A Dutch survey showed that
30% of patients have experienced conse-
quences of COVID-19 on their treatment
and follow-up visits, which makes pa-
tients very concerned about the impact
of these decisions on their cancer
outcome (de Joode et al., 2020).
In our opinion, TERAVOLT is an
example of global collaborative commit-
ment which, by leveraging the exceptional
professional skills, commitment, and pas-
sion of its partners, has been able to
significantly support thoracic cancer
care under challenging circumstances
created by the COVID-19 pandemic. We
hope this registry serves as a model for
future collaborative cancer research, to
help patients benefit from global efforts
to address key issues in future research
with a TERAVOLT-like approach.
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